Bioinformatics analysis of potential common pathogenic mechanisms for COVID-19 infection and primary Sjogren’s syndrome

Hong Luo¹ and Xia Zhou¹,²,³,⁴*

¹Department of Tuberculosis and Respiratory, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Hubei Clinical Research Center for Infectious Diseases, Wuhan, China, ³Wuhan Research Center for Communicable Disease Diagnosis and Treatment, Chinese Academy of Medical Sciences, Wuhan, China, ⁴Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, Wuhan, China

Background: Accumulating evidence has revealed that the prevalence of Coronavirus 2019 (COVID-19) was significantly higher in patients with primary Sjogren’s syndrome (pSS) compared to the general population. However, the mechanism remains incompletely elucidated. This study aimed to further investigate the molecular mechanisms underlying the development of this complication.

Methods: The gene expression profiles of COVID-19 (GSE157103) and pSS (GSE40611) were downloaded from the Gene Expression Omnibus (GEO) database. After identifying the common differentially expressed genes (DEGs) for pSS and COVID-19, functional annotation, protein-protein interaction (PPI) network, module construction and hub gene identification were performed. Finally, we constructed transcription factor (TF)-gene regulatory network and TF-miRNA regulatory network for hub genes.

Results: A total of 40 common DEGs were selected for subsequent analyses. Functional analyses showed that cellular components and metabolic pathways collectively participated in the development and progression of pSS and COVID-19. Finally, 12 significant hub genes were identified using the cytoHubba plugin, including CMPK2, TYMS, RRM2, HERC5, IFI44L, IFI44, IFIT2, IFIT1, IFIT3, MX1, CDCA2 and TOP2A, which had preferable values as diagnostic markers for COVID-19 and pSS.

Conclusions: Our study reveals common pathogenesis of pSS and COVID-19. These common pathways and pivotal genes may provide new ideas for further mechanistic studies.

KEYWORDS
primary Sjogren’s syndrome, COVID-19, differentially expressed genes, hub genes, pathogenesis
Introduction

Primary Sjogren’s syndrome (pSS) is one of the most common systemic autoimmune disorders, frequently accompanied by a variety of specific autoantibodies, such as antinuclear antibodies (ANAs), antibodies against Ro/Sjogren’s syndrome-related antigen A (SSA) and La/Sjogren’s syndrome-related antigen B (SSB), and hypergammaglobulinemia (1, 2). The prevalence of pSS is about 60 cases per 100,000 inhabitants (3) and there is a significant gender distribution difference, with the number of male patients to female patients ratio being about 1:9 (4). It is marked by lymphocytic infiltration of exocrine glands, such as lacrimal glands, salivary glands and other exocrine glands, characterized by oral and ocular dryness. At least one-third of patients with pSS may have multiple organ function impairment, such as severe thrombocytopenic purpura, primary biliary cirrhosis, and interstitial pneumonia, which can seriously compromise the patient’s prognosis, and 5% of patients may develop lymphoma (5).

The etiology and pathogenesis of pSS are still not fully elucidated and may be related to various factors such as infection, genetics and sex hormone abnormalities. Among them, viral infections are more closely related to pSS. Epstein-Barr virus (EBV), cytomegalovirus (CMV) and hepatitis C virus (HCV) may play an important role in the pathogenesis of pSS.

EBV, a DNA virus, was the first virus identified in association with pSS. EBV can affect the host immune system by directly infecting lymphocytes and indirectly regulating the expression of viral antigens through immunomodulatory mechanisms (6). The DNA component of EBV has been found to be detectable in the epithelial cells of saliva and lacrimal glands of patients with pSS (7). Studies have reported that EBV can induce autoimmune disorders in pSS through type I interferon, molecular mimicry and ectopic lymphoid-like structures (ELS), a feature of pSS pathogenesis. EBV promotes the development and progression of pSS by inducing TLR to promote IFN-1 production by dendritic cells (8, 9). In addition, the molecular mimicry between pSS autoantigens and EBV-associated antigens in the serum of pSS patients suggests that EBV infection may be involved in pathogenesis through molecular mimicry mechanism (10). Moreover, EBV can invade the ELS and thus contribute to the growth and differentiation of self-reactive B cells in pSS patients (11). CMV is a double-stranded DNA virus. It was found that CMV IgG concentrations were higher in the control group than in the pSS patient group, implying that CMV infection may be associated with the development of pSS, however, this needs to be confirmed by further clinical studies (12). HCV is a RNA virus capable of causing chronic hepatitis, cirrhosis and hepatocellular carcinoma. The pSS-characteristic salivary gland lymphocyte infiltration was found in patients with hepatitis C (13). Therefore, it was hypothesized that HCV infection might be associated with the development of SS and further studies are needed to confirm the relationship between HCV and pSS. However, although viruses such as EBV, CMV and HCV have been found to influence the pathogenesis of pSS, there are still relatively few studies focusing on COVID-19 and pSS.

Currently, Coronavirus 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is ravaging the world, which is posing an ongoing challenge to global health (14). Globally, as of 8 April 2022, there have been 494,587,638 confirmed cases of COVID-19, including 6,170,283 deaths (https://covid19.who.int/). In addition to imposing a severe burden on global healthcare systems, the epidemic is also posing a serious challenge to the management of patients with “inflammatory autoimmune systemic diseases”, including primary Sjogren’s syndrome (15, 16). Multiple studies have reported that a significantly higher prevalence of COVID-19 has been observed in patients with pSS than in the general population (17, 18). Immune dysfunction, as well as the use of immunosuppressive therapies, have been reported to predispose pSS patients to severe bacterial and viral infections (18), however, the underlying mechanism of this phenomenon is still not fully elucidated.

Exploring the common transcriptional profile of pSS and COVID-19 may provide new insights into common pathogenesis of the two diseases. In this study, we aimed to identify pivotal genes associated with the pathogenesis of pSS complicated with COVID-19. Two datasets downloaded from the GEO database (GSE30999 and GSE28829) were analyzed. Integrated bioinformatics and enrichment analysis were used to identify common DEGs and their functions in COVID-19 and pSS. In addition, a PPI network was constructed using the STRING database and Cytoscape software (version 3.9.1) to analyze the gene modules and identify hub genes. Finally, we identified 12 important hub genes and further constructed TF-gene regulatory network and TF-miRNA regulatory network for these genes. The hub genes identified in this study between COVID-19 and pSS are expected to provide new insights into the biological mechanisms of these two diseases.

Materials and methods

Datasets preparation

GEO (www.ncbi.nlm.nih.gov/geo) is a large database containing gene expression for multiple diseases, which is publicly available and free of charge (19). GSE157103 (20) dataset contains 100 COVID-19 samples and 26 non-COVID-19 samples, which used high throughput sequencing technology based on Illumina NovaSeq 6000 platform. GSE40611 (21) dataset consists of 17 pSS tissues and 18 control tissues, which was based on Affymetrix Human Genome U133 Plus 2.0 Array platform.
Identification of shared DEGs between COVID-19 and primary Sjogren’s syndrome

GEO2R (22) (www.ncbi.nlm.nih.gov/geo/geo2r/) is an online web-based tool that can be employed to compare and analyze gene expression between different sample groups. Networkanalyst (23) (www.networkanalyst.ca/) is an online visual analytics platform that enables gene expression differential analysis and enrichment analysis, meta-analysis, protein-protein interaction network analysis, and integrated analysis of multiple datasets. In this study, Networkanalyst was used to identify DEGs for GSE157103 and we employed GEO2R to analyze DEGs for GSE40611. Genes with adjusted P-value < 0.05 and |log2 fold change (log2FC)| > 1.0 were considered DEGs. The R language package VennDiagram (24) was used to obtain shared DEGs between the GSE157103 and GSE40611 datasets.

Gene ontology and KEGG enrichment analysis

KEGG Orthology Based Annotation System (25) (KOBAS; http://bioinfo.org/kobas) is a database developed by Peking University for annotation and identification of enriched pathways and diseases. Gene ontology and KEGG enrichment analysis were performed to analyze the potential function of DEGs by using the KOBAS 3.0 database. Adjusted P-value < 0.05 was considered statistically significant.

Construction of protein–protein interaction network and module analysis

Search Tool for the Retrieval of Interacting Genes (STRING (26); http://string-db.org) (version 11.5) is a database for the study of protein interactions with information on more than 14,000 species, more than 60 million proteins, and more than 20 billion interactions, which include both direct physical interactions as well as indirect functional correlations. The protein-protein interaction (PPI) interaction network of the common DEGs was constructed by STRING with an interaction score > 0.4. Cytoscape software (27) (version 3.9.0) was used to visualize the PPI network and we used the Cytoscape plug-in Molecular Complex Detection (MCODE (28)) to analyze core functional modules. The parameters were set as follows: degree cutoff = 2, max depth = 100, node score cutoff = 0.2 and K-core = 2. Then KOBAS 3.0 was applied to carry out KEGG and GO analysis of the genes in each module.

Identification and analysis of hub genes

The hub genes were selected by a plug-in cytoHubba (29) of Cytoscape and then seven algorithms (Closeness, MCC, Degree, MNC, Radiality, Stress and EPC) were used to confirm the final hub genes, which were visualized by Venn diagram. GeneMANIA (30) (http://genemania.org), an online tool that can predict gene interactions, was utilized to construct a co-expression network of identified hub genes.

Construction of TF-gene regulatory network and TF-miRNA regulatory network

In this study, TF-gene regulatory network and TF-miRNA regulatory network were constructed by utilizing the Networkanalyst platform. In the case of TF-gene regulatory network, the ENCODE (31) (https://www.encodeproject.org/) database, which is included in the Networkanalyst platform, was been used. As for TF-miRNA regulatory network, it was acquired from the RegNetwork (32) (http://www.regnetworkweb.org) database, which is incorporated in the NetworkAnalyst platform.

ROC curves of hub genes

ROC curves were constructed and the area under the ROC curve (AUC) was calculated separately to evaluate the diagnostic performance of the hub genes on COVID-19 and pSS using the R packages “pROC” (33).

Results

Identification of DEGs and shared genes between COVID-19 and primary Sjogren’s syndrome

The overall flow chart of this study was shown in Figure 1. For GSE157103 dataset, a total of 1003 DEGs were identified, among which 554 genes were up-regulated and 449 genes were down-regulated (Figure 2A). Based on the GSE40611 dataset, we identified 351 DEGs including 291 upregulated genes and 60 downregulated genes (Figure 2B). Then by taking the intersection of DEGs of GSE157103 dataset and GSE40611 dataset, there were 40 shared DEGs selected, which were visualized by Venn diagrams (Figure 2C).
FIGURE 1
Workflow diagram of this study.

FIGURE 2
Volcano diagram and Venn diagram. (A) The volcano map of GSE157103. (B) The volcano map of GSE40611. Upregulated genes are colored in red; downregulated genes are colored in green. (C) The two datasets showed an overlap of 40 DEGs.
GO and KEGG pathway enrichment analysis

For GO enrichment analysis, the top five significant terms showed that the shared DEGs were mainly involved in protein binding, cytoplasm, cytosol, nucleus and nucleoplasm (Figure 3A). In terms of KEGG pathway enrichment analysis, the top five significant terms were metabolic pathways, pyrimidine metabolism, cell cycle, hepatitis C and cytokine-cytokine receptor interaction. These results forcefully indicated that cellular component and metabolic pathways collectively participated in the development and progression of both inflammatory diseases (Figure 3B).

Identification and functional analysis of hub genes

By applying the seven algorithms of plug-in cytoHubba, we screened the top 20 hub genes. Through the intersection of Venn diagrams, 12 common hub genes were finally identified, including CMPK2, TYMS, RRM2, HERC5, IFI44L, IFI44, IFIT2, IFIT1, IFIT3, MX1, CDCA2 and TOP2A (Figure 6A). According to GeneMANIA database, we constructed a complex gene interaction network to decipher the biological functions of these hub genes, with the co-expression of 60.37%, physical interactions of 33.91%, co-localization of 3.46%, predicted of 2.15% and pathway of 0.10% (Figure 6B). Twenty genes associated with the 12 hub genes were identified, and the results showed that they were mainly linked to type I interferon, response to virus, regulation of viral genome replication, regulation of viral life cycle, viral life cycle, deoxyribonucleotide metabolic process and adenylyltransferase activity.

Protein–protein interaction network analysis and submodule analysis

The PPI network included 40 nodes and 149 edges, of which the PPI enrichment P-value was lower than 1.0e−16 (Figure 4). By visualizing the PPI network using Cytoscape software, the redder the color of the gene in the network, the higher the connectivity of the gene with other genes. A key gene module, including 25 shared DEGs, was obtained by applying the MCODE plug-in of Cytoscape (Figure 5A). GO enrichment analysis of these genes in the module showed that these genes were mainly associated with cytoplasm, defense response to virus, response to virus, cytosol and type I interferon signaling pathway (Figure 5B). KEGG enrichment analysis of these genes in the module indicated that these genes were mainly related to pyrimidine metabolism, cell cycle, p53 signaling pathway, progestosterone-mediated oocyte maturation and cellular senescence (Figure 5C).

TF-gene interactions and TF-miRNA co-regulatory network

TFs which can interact with the 12 hub genes were predicted by Networkanalyst, and the TF-gene regulatory network was plotted and visualized by Cytoscape (Figure 7). The network contains 124 TFs, 134 nodes and 165 edges. These TFs regulate more than one hub gene in the network, which demonstrated the high interaction of TFs with hub genes. Subsequently, TF-miRNA co-regulatory network was constructed using NetworkAnalyst, which predicted the interaction of miRNA and TF with hub genes (Figure 8). This interaction may be responsible for the regulation of hub gene expression. The network included 65 nodes and 85 edges and 12 miRNAs and 45 TF genes interacted with hub genes.
ROC curves of hub genes

We assessed the diagnostic efficacy of the 12 hub genes by plotting ROC curves. In the COVID-19 dataset, TYMS (AUC:0.952), RRM2 (AUC:0.954), CDCA2 (AUC:0.946) and TOP2A (AUC:0.958) exhibited good diagnostic efficiency for differentiating the patients with SARS-CoV-2 from healthy controls (Figure 9A). In the pSS dataset, CMPK2 (AUC:0.922), TYMS (AUC:0.918), IFI44 (AUC:0.925), IFIT1 (AUC:0.948), IFIT3 (AUC:0.944) and MX1 (AUC:0.935) exhibited preferable diagnostic performance for differentiating pSS patients from healthy controls (Figure 9B).
FIGURE 6
Venn diagram and co-expression network of hub genes. (A) The Venn diagram showed 12 overlapping hub genes screened by 7 algorithms. (B) Hub genes and their co-expression genes were analyzed via GeneMANIA.

FIGURE 7
Network for TF-gene interaction with hub genes. The highlighted blue color node represents the hub genes and other nodes represent TF-genes.
Evidence has indicated that the prevalence of COVID-19 was significantly higher in patients with pSS compared to the general population. A variety of viruses (EBV, CMV and HCV) have been found to be closely associated with the development of pSS, but there are still fewer studies on COVID-19 and pSS. Hence, we attempted to explore the shared molecular biological function and pathways between COVID-19 and pSS, and to determine the interrelationship between COVID-19 and pSS.

In this study, 40 shared DEGs of COVID-19 and pSS have been identified. After constructing the PPI network of common DEGs, we identified 12 hub genes (CMPK2, TYMS, RRM2, HERC5, IFI44L, IFI44, IFIT2, IFIT1, IFIT3, MX1, CDCA2, and TOP2A).

Seven genes have been reported to be related to the pathological mechanism of COVID-19 and pSS. CMPK2 (Cytidine/uridine monophosphate kinase 2) is a thymidylate kinase, known to be associated with mitochondrial DNA (mtDNA) synthesis, and may attenuate the severity of acute respiratory distress syndrome (ARDS), a common complication of severe COVID-19, by rate-limiting for mtDNA synthesis. In pSS samples, CMPK2 was reported to be upregulated and linked to the extent of immune cell infiltration, mitochondrial respiratory chain complexes, and other molecular processes associated with pSS.
mitochondrial metabolic pathways (36). HERC5 (HECT and RLD domain containing E3 ubiquitin protein ligase 5) is an antiviral immune protein which is induced by interferon. It can inhibit replication of hepatitis C (HCV), influenza A (IAV), human immunodeficiency virus (HIV), SARS-CoV-2 and other viruses by mediating ISGylation of protein targets induced by type I interferon (37–39). IFI44L (Interferon(IFN) Induced Protein 44 Like) is a type-1 I interferon-stimulated gene, induced by several different viruses. IFI44L expression was significantly higher in pSS patients than in controls and was markedly increased after IFN-α or IFN-β stimulation (40, 41). In addition, this gene was also significantly upregulated in SARS-CoV-2 infected cardiac tissues (42). As a feedback regulator of IFN responses, IFI44L can facilitate virus replication via modulating innate immune responses induced after virus infections (43). IFIT (Interferon-induced protein with tetratricopeptide repeats) genes are interferon-stimulated genes and consist of four genes, IFIT1, IFIT2, IFIT3 and IFIT5. The expression of IFIT genes is low in multiple cell types, while viral infection can increase their expression. In pathological conditions, they inhibit viral replication by binding and modulating the function of cellular and viral proteins (44, 45). IFIT1, IFIT2 and IFIT3 have been shown to be upregulated in cells infected with SARS-CoV-2, indicating activation of the interferon innate response, which could be regarded as potential drug targets for the treatment of COVID-19 (46–48). Moreover, they may upregulate the expression of CXCL10 which induces lymphocyte chemotaxis and may inhibit the replication of viruses. These molecules may play a critical role in the innate immune response in response to viruses (49). MX1 (Myxovirus resistance 1) encodes a guanosine triphosphate (GTP) metabolizing protein in the cellular antiviral response. The encoded protein is induced by type I and type II interferons and antagonizes the replication process of multiple different RNA and DNA viruses. Through binding to viral nucleoproteins, MX1 can interfere with the transcription of influenza viruses (50–52). Several studies have revealed that MX1 is overexpressed in COVID-19 group compared to control group, due to the activation of MX1 responding to new viruses for which the body has no immune defense (53–55). In addition, the baseline level of MX1 help to identify SARS-CoV-2-positive patients and help to differentiate patients who are inclined to different outcomes (56). Similarly, the expression of MX1 was significantly upregulated in the pSS (57). For the remaining five hub genes (TYMS, CDC2A, TOP2A, RRM2 and IFI44), there are no studies reporting their role in COVID-19 or pSS, which emphasizes its importance in future research.

In this study, GO enrichment analysis indicated that the type I interferon signaling pathway is common pathogenesis of COVID-19 and pSS. Furthermore, based on published publications, we hypothesized that type I interferon might be a shared mechanism of COVID-19 and pSS.

Interferon (IFN) is a class of cytokines with antiviral effects that directly induce anti-pathogenic immune responses by controlling the inflammatory response and coordinating the immune response, thereby resisting invasion and infection by foreign pathogens (58). Interferons induced by viral infections can be produced through different signaling pathways, eventually leading to the transcription and expression of hundreds of IFN-stimulated genes (ISGs), which further exert antiviral effects (59). Interferons are classified into three major classes: type I, II, and III interferons. Type I interferons (IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω) are secreted by virus-infected cells, type II interferons (IFN-γ) are secreted by activated T cells, and type III IFN (IFN-λ) binds to type III IFN receptors (IFNLR) and is preferentially expressed on epithelial cells and certain bone marrow cells (60). Type I interferon is the main type of interferon that can exert antiviral effects.

Although IFN has anti-multiviral effects, it does not kill viruses directly, but rather inhibits the replication process by producing antiviral proteins (61). Studies have demonstrated that IFN can induce the expression of antiviral proteins upon viral infection (62). IFN-α can significantly enhance cellular susceptibility to microorganisms by upregulating Toll-like receptors (TLRs) expression or the expression of transduction molecules and kinases involved in TLR signaling (63). Moreover, IFN-α strongly increases the differentiation of T cells and enhances cellular immunity (64). In addition to its effect on T cells, IFN can also promote the proliferation of B cells and enhance humoral immune responses (65). In summary, there are two main antiviral mechanisms of IFN: one is acting on viruses, such as interfering with viral replication, and the other is acting on cells to strengthen the immune function of the body.

There is substantial evidence that type I interferon plays an important role in the pathogenesis and progression of pSS due to immune dysregulation (66). For example, it can influence the immune response to pSS, participating in the activation of antiviral responses and controlling immune responses through interactions with the corresponding receptors (67). An important role of type I interferon is to induce immune activation, which affects the production and regulation of pro-inflammatory cytokines and other mediators (68). Monocytes are stimulated by type I interferon to differentiate into dendritic cells and stimulate immature dendritic cells to express chemokines and costimulatory molecules that facilitate their homing to secondary lymphoid organs, thereby activating adaptive immunity (69). In addition, macrophages are stimulated by interferon to enhance phagocytosis. BAFF (B cell activating factor) is known to be involved in the pathogenesis of pSS, as it is upregulated in monocytes in response to type I and type II IFN and promotes B-cell
survival (70). In addition to monocytes, macrophages, dendritic cells and salivary gland epithelial cells also express BAFF in response to IFN stimulation (71, 72). Transgenic mice that overproduce BAFF exhibit increased B cell proliferation, increased germinal center responses, autoantibody production, and increased numbers of immune complexes (73). This suggests that IFN (especially IFN type I) promotes the development of pSS by inducing innate immunity, activating adaptive immunity, and regulating inflammatory cytokines and antibody levels. Although previous studies have explored the pivotal genes associated with COVID-19 and pSS, respectively. However, few studies have explored the common molecular mechanisms between the two through bioinformatic approaches. In this study, we explored and identified common DEGs, hub genes and TFs of COVID-19 and pSS for the first time, which helped to further elucidate the pathogenesis of both. However, our study also has some limitations. First, this study requires external validation to verify our findings; second, the function of hub genes needs to be further validated in an in vitro model, which will be the focus of our future work.

In conclusion, we identified common DEGs for COVID-19 and pSS and performed enrichment and PPI network analysis. We found that COVID-19 and pSS share pathogenic mechanism that may be mediated by specific hub genes. This study provides a potential direction for further investigation of the molecular mechanisms of COVID-19 and pSS.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

Author contributions

HL performed data analyses and wrote the manuscript draft. XZ revised the manuscript. All authors read and approved the final manuscript. All authors contributed to the article and approved the submitted version.

Funding

This research was supported financially by the Funding of Wuhan Health Planning Commission Program (WX15B21, to XZ).

Acknowledgements

We thank the authors of the GSE157103 and GSE40611 datasets for their contribution.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Mavragani CP. Mechanisms and new strategies for primary sjögren’s syndrome. Ann Rev Med (2017) 68:331–43. doi: 10.1146/annurev-med-043015-123513
2. Li N, Li L, Wu M, Li Y, Yang J, Wu Y, et al. Integrated bioinformatics and validation reveal potential biomarkers associated with progression of primary sjögren’s syndrome. Front Immunol (2021) 12:697157. doi: 10.3389/fimmu.2021.697157
3. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis (2015) 74(11):1983–9. doi: 10.1136/annrheumdis-2014-205375
4. Fox RI. Sjögren’s syndrome. Lancet (2005) 366(9482):321–31. doi: 10.1016/S0140-6736(05)66990-5
5. Kapsogeorgou EK, Voulgaris M, Tzioufas AG. Predictive markers of lymphomagenesis in sjögren’s syndrome: From clinical data to molecular stratification. J Autoimmun (2019) 104:102316. doi: 10.1016/j.jaut.2019.102316
6. Drabog A, Izazrugaza JM, Houen G. How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases? Curr Opin Rheumatol (2016) 28(4):398–404. doi: 10.1097/BOR.0000000000000289
7. Saito I, Servenius B, Compton T, Fox RI. Detection of Epstein-barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with sjögren’s syndrome. J Exp Med (1998) 187(6):21941–8. doi: 10.1084/jem.187.6.2191
8. Liu X, Sadaoka T, Krogmann T, Cohen H. Epstein-Barr Virus (Ebv) tegument protein Bglf2 suppresses type I interferon signaling to promote ebv reactivation. J Virol (2020) 94(11):e00258–20. doi:10.1128/jvi.00258-20
9. Shimizu T, Nakamura H, Takatani A, Umeda M, Horai Y, Kurushima S, et al. Activation of toll-like receptor 7 signaling in labial salivary glands of primary sjögren’s syndrome patients. Clin Exp Immunol (2019) 196(1):39–51. doi:10.1111/cei.13242
10. Navone R, Lunardi C, Gerli R, Tinazzi E, Peterlana D, Bason C, et al. Identification of tear lipocalin as a novel autoantigen target in sjögren’s syndrome. J Autoimmun (2005) 25(3):229–34. doi: 10.1016/j.jaut.2005.09.021
11. Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N, et al. Implication of Epstein-Barr Virus infection in disease-specific autoreactive b cell activation in ectopic lymphoid structures of sjögren’s syndrome. Arthritis Rheumatol (Hoboken NJ) (2014) 66(9):2545–57. doi: 10.1002/art.38726
12. Kiryv S, Arango MT, Ehrenfeld M, Tehori O, Shoenfeld Y, Anaya JM, et al. Infection and autoimmunity in sjögren’s syndrome: A clinical study and
comprehensive review. J Autoimmun (2014) 51:17–22. doi: 10.1016/j.jaut.2014.03.002

13. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, et al. Lymphocytic sialadenitis of sjögren’s syndrome associated with chronic hepatitis c virus liver disease. Lancet (1992) 339(8789):321–3. doi: 10.1016/0140-6736(92)91645-8

14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5

15. Ferri C, Giugliani R, Daimondo V, L’Andolina M, Tavoni A, Cecchetti R, et al. Covid-19 and rheumatic autoimmune systemic diseases: Report of a large Italian patients series. Clin Rheumatol (2020) 39(11):3195–204. doi: 10.1007/s10067-020-05334-7

16. Chowdhury F, Grigoriadou S, Bombardieri M. Severity of covid-19 infection in primary sjögren’s syndrome and the emerging evidence of covid-19-induced keratoconjunctivitis. Clin Exp Rheumatol (2020) 39 Suppl 105:216–22. doi: 10.5563/cephoenix/rk/Ctxta

17. Akaiya S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical ten years on. Ann Rheum Dis (2021) 80(7):1102. doi: 10.3390/v11070516

18. Lu and Zhou 10.3389/fimmu.2022.845209

19. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical ten years on. J Autoimmun (2014) 51:17–22. doi: 10.1016/j.jaut.2014.03.002
viral ribonucleoprotein complex assembly. J Virol (2012) 86(24):13445–55. doi: 10.1128/jvi.01682-12

56. Maras JS, Sharma S, Bhat A, Ronge S, Aggrawal R, Gupta E, et al. Multi-omics analysis of respiratory specimen characterizes baseline molecular determinants associated with sars-Cov-2 outcome. Science (2021) 248(102823). doi: 10.1126/science.1251121

57. Papinska J, Bagavant H, Gmyrek GB, Deshmukh US. Pulmonary involvement in a mouse model of sjögren’s syndrome induced by sting activation. Int J Mol Sci (2020) 21(12):4512. doi: 10.3390/ijms21124512

58. Wang W, Xu L, Su J, Peppelenbosch MP, Pan Q. Transcriptional regulation of antiviral interferon-stimulated genes. Trends Microbiol (2017) 25(7):573–84. doi: 10.1016/j.tim.2017.01.001

59. Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat covid-19. Cell Host Microbe (2020) 27(6):870–8. doi: 10.1016/j.chom.2020.05.008

60. Kolenko SV, Rivera A, Parker D, Durbin JE. Type III IFNs: Beyond antiviral protection. Semin Immunol (2019) 43:101303. doi: 10.1016/j.smim.2019.101303

61. Zhang R, Tang J. Evasion of I interferon-mediated innate immunity by pseudorabies virus. Front Microbiol (2021) 12:801257. doi: 10.3389/fmicb.2021.801257

62. Liu SY, Sanchez DJ, Cheng G. New developments in the induction and antiviral effects of type I interferon. Curr Opin Immunol (2011) 23(1):57–64. doi: 10.1016/j.coi.2010.11.003

63. Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol (2018) 323:63–73. doi: 10.1016/j.jneuroim.2018.06.012

64. Chenna Narendra S, Chalise JP, Biggs S, Kalinke U, Magnusson M. Regulatory T-cells mediate IFN-A-induced resistance against antigen-induced arthritis. Front Immunol (2018) 9:285. doi: 10.3389/fimmu.2018.00285

65. Graalman T, Borst K, Manchanda H, Vaas L, Bruhn M, Graalman L, et al. B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner. Ann Rheum Dis (2021) 80(12):1537–44. doi: 10.1136/annrheumdis-2021-220435

66. Del Papa N, Minniti A, Lorini M, Carbonelli V, Maglione W, Pignataro F, et al. The role of interferons in the pathogenesis of sjögren’s syndrome and future therapeutic perspectives. Biomolecules (2021) 11(2):251. doi: 10.3390/biom11020251

67. Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol (2018) 9:2061. doi: 10.3389/fimmu.2018.02061

68. Bodewes ILA, Versnel MA. Interferon activation in primary sjögren’s syndrome: Recent insights and future perspective as novel treatment target. Expert Rev Clin Immunol (2018) 14(10):817–29. doi: 10.1080/1744666x.2018.1519396

69. Luo S, Wu R, Li Q, Zhang G. Epigenetic regulation of Ifi44l expression in monocytes affects the functions of monocyte-derived dendritic cells in systemic lupus erythematosus. J Immunol Res (2022) 2022:4053038. doi: 10.1155/2022/4053038

70. Nocturne G, Mariette X. B cells in the pathogenesis of primary sjögren syndrome. Nat Rev Rheumatol (2018) 14(3):133–45. doi: 10.1038/nrrheum.2018.1

71. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. Tto3 dews ii pathophysiology report. Ocular Surface (2017) 15(3):438–310. doi: 10.1016/j.jtos.2017.05.011

72. Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol (2012) 90(5):498–504. doi: 10.1038/icb.2012.10

73. Thompson N, Isenberg DA, Jury EC, Ciurtin C. Exploring baff: Its expression, receptors and contribution to the immunopathogenesis of sjögren’s syndrome. Rheumatol (Oxford) (2016) 55(9):1548–55. doi: 10.1093/rheumatology/kev420